Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/8/2026
- S&P 500, Nasdaq rise as tech, chipmakers rebound
- Oil prices settle $1 higher after Iran and Israel say they have halted attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Powerful Philippine quake leaves at least 32 feared dead, survivors recount fear
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
- Salesforce to acquire metering platform M3TER for consumption billing
- SpaceX sets $135 price for blockbuster IPO, upending Wall Street convention
Kymera Therapeutics (KYMR) Misses Q1 EPS by 5c
May 3, 2022 7:17 AM EDTKymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.05 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $9.62 million versus the consensus estimate of $16.23 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
... More